IngbarDH, NairS.Oxygen transport in the critically ill patient. Appl Cardiopulm Physiol1989;3:97โ120.
3.
KahnRC, ZaroulisC, GoetzW, HowlandWS. Hemodynamic oxygen transport and 2,3-diphosphoglycerate changes after transfusion of patients in acute respiratory failure. Intensive Care Med1986;12:22โ25.
4.
WinslowRM. Optimal hematologic variables for oxygen transport, including P50, hemoglobin cooperativity, hematocrit, acid-base status, and cardiac function. Biomater Artif Cells Artif Org1988;16:149โ171.
5.
GeyerRP. Fluorocarbon-polyol artificial blood substitutes. N Engl J Med1973;289:1077โ1082.
6.
ClarkLC, GollanF.Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science1966;152:1755โ1756.
7.
GeyerRP. "Bloodless" rats through the use of artificial blood substitutes. Fed Proc1975;34:1499โ1505.
8.
TremperKK, CullenBF. U.S. clinical studies of the treatment of anemia with Fluosol-DA 20%. Artif Organs1984;8:19โ24.
9.
TremperKK, AndersonST. Perfluorochemical emulsion oxygen transport fluids: A clinical review. Ann Rev Med1985;309:313.
10.
MitsunoT, OhyanagiH.Present status of clinical studies of Fluosol-DA (20%) in Japan. Intern Anesthesiol Clin1985;23:169โ184.
11.
TremperKK, FriedmanAE, LevineEM, LapinR, CamarilloD.The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA. N Engl J Med1982;307:277โ283.
FormanMB, BinghamS, KopelmanHA, . Reduction of infarct size with intracoronary perfluorochemical in a canine preparation of reperfusion. Circulation1985;71:1060โ1068.
17.
ClemanM, JaffeeCC, WohlgelernterD.Prevention of ischemia during percutaneous transluminal coronary angioplasty by transcatheter infusion of oxygenated Fluosol DA 20%. Circulation1986;74:555โ562.
18.
JaffeCC, WohlgelernterD, CabinH, . Preservation of left ventricular ejection fraction during percutaneous transluminal coronary angioplasty by distal transcatheter coronary perfusion of oxygenated Fluosol DA 20%. Am Heart J1988;115:1156โ1164.
19.
PeerlessSJ, IshikawaR, HunterIG, PeerlessMJ. Protective effect of Fluosol-DA in acute cerebral ischemia. Stroke1981;12:558โ563.
20.
NagasawaS, HandaH, YonekawaY, OdaY, TsudaY, YokoyamaK.Effects of a transfusion with a blood substitute (Fluosol-DA, 20%). Part II: Human cerebral blood flow. Neurol Res1983;5:19โ30.
21.
ReindorfCA, Kurantsin-MillsJ, AlloteyJB, CastroO.Perfluorocarbon compounds: Effects on the rheological properties of sickle eythrocytes in vitro. Am J Hematol1985;19:229โ236.
22.
BandoK, TeramotoS, TagoM, . Oxygenated perfluorocarbon, recombinant human superoxide dismutase, and catalase ameliorate free radical induced myocardial injury during heart preservation and transplantation. J Thorac Cardiovasc Surg1988;96:930โ938.
23.
RockwellS.Perfluorochemical emulsions as adjuncts to radiotherapy. Biomater Artif Cells Artif Organs1988;16:519โ532.
24.
MartinDF, PorterEA, RockwellS, FischerJJ. Enhancement of tumor radiation response by the combination of perfluorochemical emulsion and hyperbaric oxygen. Int J Radiat Oncol Biol Phys1987;13:747โ751.
25.
RoseC, LustigR, McIntoshN, TeicherB.Clinical trial of Fluosol DA 20% in advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys1986;12:1325โ1327.
26.
TeicherBA, McIntoshNL, RoseCM. Effect of various oxygenation conditions and Fluosol DA on cancer chemotherapeutic agents. Biomater Artif Cells Artif Organs1988;16:533โ546.
27.
KuwamuraK, KokunaiT, TamakiN, MatsumotoS.Synergistic effect of perfluorochemicals on BCNU chemotherapy. J Neurosurg1982;57:467โ471.
28.
TeicherBA, KazoJS, MerrillWW, FildermanAE, RoseCM. Effect of Fluosol-DA 20 on the antitumor activity and pulmonary toxicity of bleomycin. Cancer Chemother Pharmacol1986;18:213โ218.
29.
VercellottiGM, HammerschmidtDE, CraddockPR, JacobHS. Activation of plasma complement by perfluorocarbon artificial blood: Probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroid prophylaxis. Blood1982;59:1299โ1304.
30.
LaneTA, KrukonisV.Reduction in the toxicity of a component of an artificial blood substitute by supercritical fluid fractionation. Transfusion1988;28:375โ378.
31.
WaxmanK, CheungCK, MasonGR. Hypotensive reaction after infusion of a perfluorochemical emulsion. Crit Care Med1984;12:609โ610.
32.
TremperKK, VercellottiGM, HammerschmidtDE. Hemodynamic profile of adverse clinical reactions to Fluosol-DA 20%. Crit Care Med1984;12:428โ431.
33.
PoliceAM, WaxmanK, TominagaG.Pulmonary complications after Fluosol administration to patients with life-threatening blood loss. Crit Care Med1985;13:96โ98.
34.
LaneTA, LamkinGE. Increased infection mortality and decreased neutrophil migration due to a component of an artificial blood substitute. Blood1986;68:351โ354.
35.
LaneTA, LamkinGE. Paralysis of phagocyte migration due to an artificial blood substitute. Blood1984;64:400โ405.
36.
VirmaniR, FinkLM, GunterK, EnglishD.Effect of perfluorochemical blood substitutes on human neutrophil function. Transfusion1984;24:343โ347.
37.
BucalaR, KawakamiM, CeramiA.Cytoxicity of a perfluorocarbon blood substitute to macrophages in vitro. Science1983;220:965โ967.
38.
JancoRL, VirmaniR, MorrisPJ, GunterK.Perfluorochemical blood substitutes differentially alter human monocyte procoagulant generation and oxidative metabolism. Transfusion1985;25:578โ582.
39.
LongDM, LongDC, MattreyRF, . An overview of perfluoroctylbromide application as a synthetic oxygen carrier and imaging agent for x-ray, ultrasound, and nuclear magnetic resonance. Biomater Artif Cells Artif Organs1988;16:411โ420.
40.
BurganAR, HerrickWC, LongDM, LongDC. Acute and subacute toxicity of 100% PFOB emulsion. Biomater Artif Cells Artif Organs1988;16:681โ682.
41.
GouldSA, SehgalLR, RosenAL, SehgalHL, MossGS. Red cell substitutes: An update. Ann Emerg Med1985;14:796โ803.
KeipertPE, AdeniranAJ, KwongS, BeneschRE. Functional properties of a new crosslinked hemoglobin designed for use as a red cell substitute. Transfusion1989;29:768โ773.
47.
GouldSA, RosenAL, SehgalLR, SehgalHL, RiceCL, MossGS. Red cell substitutes: Hemoglobin solution or fluorocarbon?J Trauma1982;22:736โ740.
ValeriCR, ZaroulisCG, VecchioneJJ, . Therapeutic effectiveness and safety of outdated human red blood cells rejuvenated to improve oxygen transport function, frozen for about 1.5 years at 8ยฐC, washed, and stored at 4ยฐC for 24 hours prior to rapid infusion. Transfusion1980;20:263โ276.
50.
RoparsC, TeisseireB, AvenardG, . Improved oxygen delivery to tissues and iron chelator transport through the use of lysed and resealed red blood cells: A new perspective on Cooley's anemia therapy. Ann NY Acad Sci1985;445:304โ315.
51.
HuntCA, BurnetteRR, MacGregorRD, StrubgeAE. Synthesis and evaluation of a prototypal artificial red cell. Science1985;230:1165โ1168.
52.
MillerIF, MayoralJ, DjordjevichL, KashaniA.Hemodynamic effects of exchange transfusions with liposome-encapsulated hemoglobin. Biomater Artif Cells Artif Organs1988;16:281โ288.
53.
BartlettRH. A critical carolโBeing an essay on anemia, suffocation, starvation, and other forms of intensive care, after the manner of Dickens. Chest1985;88:687โ693.
